{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:19:18Z","timestamp":1787667558919,"version":"build-2736575974"},"reference-count":53,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T00:00:00Z","timestamp":1773273600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Patient"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40271-026-00811-8","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:21:48Z","timestamp":1773310908000},"page":"619-635","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Stated Preferences for Systemic Treatments for Prostate Cancer: A Targeted Review of the Discrete-Choice Experiment Literature"],"prefix":"10.1007","volume":"19","author":[{"given":"Neeraj","family":"Agarwal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3129-7268","authenticated-orcid":false,"given":"Brett","family":"Hauber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua","family":"Coulter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Savanna","family":"Darnell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verity","family":"Watson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sean P.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,12]]},"reference":[{"key":"811_CR1","unstructured":"International Agency for Research on Cancer. Globocan fact sheet. 2022. https:\/\/gco.iarc.who.int\/media\/globocan\/factsheets\/populations\/900-world-fact-sheet.pdf. Accessed 2 Sep 2025."},{"issue":"6","key":"811_CR2","doi-asserted-by":"publisher","first-page":"1082","DOI":"10.1097\/JU.0000000000003452","volume":"209","author":"W Lowrance","year":"2023","unstructured":"Lowrance W, Dreicer R, Jarrard DF, Scarpato KR, Kim SK, Kirkby E, et al. Updates to advanced prostate cancer: AUA\/SUO guideline (2023). J Urol. 2023;209(6):1082\u201390. https:\/\/doi.org\/10.1097\/JU.0000000000003452.","journal-title":"J Urol"},{"issue":"6","key":"811_CR3","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/j.annonc.2023.02.015","volume":"34","author":"K Fizazi","year":"2023","unstructured":"Fizazi K, Gillessen S. Updated treatment recommendations for prostate cancer from the ESMO Clinical Practice Guideline considering treatment intensification and use of novel systemic agents. Ann Oncol. 2023;34(6):557\u201363. https:\/\/doi.org\/10.1016\/j.annonc.2023.02.015. (clinicalguidelines@esmo.org EGCEa.).","journal-title":"Ann Oncol"},{"issue":"5","key":"811_CR4","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","volume":"20","author":"K Fizazi","year":"2019","unstructured":"Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, et al. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol. 2019;20(5):686\u2013700. https:\/\/doi.org\/10.1016\/S1470-2045(19)30082-8.","journal-title":"Lancet Oncol"},{"issue":"4","key":"811_CR5","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1056\/NEJMoa1702900","volume":"377","author":"ND James","year":"2017","unstructured":"James ND, de Bono JS, Spears MR, Clarke NW, Mason MD, Dearnaley DP, et al. Abiraterone for prostate cancer not previously treated with hormone therapy. N Engl J Med. 2017;377(4):338\u201351. https:\/\/doi.org\/10.1056\/NEJMoa1702900.","journal-title":"N Engl J Med"},{"issue":"20","key":"811_CR6","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1200\/JCO.20.03488","volume":"39","author":"KN Chi","year":"2021","unstructured":"Chi KN, Chowdhury S, Bjartell A, Chung BH, de Pereira Santana Gomes AJ, Given R, et al. Apalutamide in patients with metastatic castration-sensitive prostate cancer: Final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol. 2021;39(20):2294\u2013303. https:\/\/doi.org\/10.1200\/JCO.20.03488.","journal-title":"J Clin Oncol"},{"issue":"32","key":"811_CR7","doi-asserted-by":"publisher","first-page":"2974","DOI":"10.1200\/JCO.19.00799","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong AJ, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Azad A, et al. ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer. J Clin Oncol. 2019;37(32):2974\u201386. https:\/\/doi.org\/10.1200\/JCO.19.00799.","journal-title":"J Clin Oncol"},{"issue":"10024","key":"811_CR8","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","volume":"387","author":"ND James","year":"2016","unstructured":"James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP, Spears MR, et al. Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. Lancet. 2016;387(10024):1163\u201377. https:\/\/doi.org\/10.1016\/S0140-6736(15)01037-5.","journal-title":"Lancet"},{"issue":"11","key":"811_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","volume":"36","author":"CE Kyriakopoulos","year":"2018","unstructured":"Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, et al. Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol. 2018;36(11):1080\u20137. https:\/\/doi.org\/10.1200\/JCO.2017.75.3657.","journal-title":"J Clin Oncol"},{"issue":"11","key":"811_CR10","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1056\/NEJMoa2001342","volume":"383","author":"K Fizazi","year":"2020","unstructured":"Fizazi K, Shore N, Tammela TL, Ulys A, Vjaters E, Polyakov S, et al. Nonmetastatic, castration-resistant prostate cancer and survival with darolutamide. N Engl J Med. 2020;383(11):1040\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2001342.","journal-title":"N Engl J Med"},{"issue":"1","key":"811_CR11","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","volume":"79","author":"MR Smith","year":"2021","unstructured":"Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, et al. Apalutamide and overall survival in prostate cancer. Eur Urol. 2021;79(1):150\u20138. https:\/\/doi.org\/10.1016\/j.eururo.2020.08.011.","journal-title":"Eur Urol"},{"issue":"23","key":"811_CR12","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","volume":"382","author":"CN Sternberg","year":"2020","unstructured":"Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, et al. Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2020;382(23):2197\u2013206. https:\/\/doi.org\/10.1056\/NEJMoa2003892.","journal-title":"N Engl J Med"},{"issue":"2","key":"811_CR13","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","volume":"6","author":"WP Harris","year":"2009","unstructured":"Harris WP, Mostaghel EA, Nelson PS, Montgomery B. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol. 2009;6(2):76\u201385. https:\/\/doi.org\/10.1038\/ncpuro1296.","journal-title":"Nat Clin Pract Urol"},{"issue":"9","key":"811_CR14","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","volume":"31","author":"C Parker","year":"2020","unstructured":"Parker C, Castro E, Fizazi K, Heidenreich A, Ost P, Procopio G, et al. Prostate cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2020;31(9):1119\u201334. https:\/\/doi.org\/10.1016\/j.annonc.2020.06.011.","journal-title":"Ann Oncol"},{"issue":"1","key":"811_CR15","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1097\/JU.0000000000004228","volume":"213","author":"ND Shore","year":"2025","unstructured":"Shore ND, De Giorgi U, Freedland SJ. Enzalutamide in men with high-risk biochemically recurrent prostate cancer: rationale and treatment considerations from EMBARK. J Urol. 2025;213(1):110\u20133. https:\/\/doi.org\/10.1097\/JU.0000000000004228.","journal-title":"J Urol"},{"issue":"5","key":"811_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-014719","volume":"7","author":"M Harrison","year":"2017","unstructured":"Harrison M, Milbers K, Hudson M, Bansback N. Do patients and health care providers have discordant preferences about which aspects of treatments matter most? Evidence from a systematic review of discrete choice experiments. BMJ Open. 2017;7(5):e014719. https:\/\/doi.org\/10.1136\/bmjopen-2016-014719.","journal-title":"BMJ Open"},{"issue":"1","key":"811_CR17","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1186\/s12885-023-11598-4","volume":"23","author":"M Zhang","year":"2023","unstructured":"Zhang M, He X, Wu J, Xie F. Differences between physician and patient preferences for cancer treatments: a systematic review. BMC Cancer. 2023;23(1):1126. https:\/\/doi.org\/10.1186\/s12885-023-11598-4.","journal-title":"BMC Cancer"},{"key":"811_CR18","unstructured":"EAU E, ESTRO, ESUR, ISUP, and SIOG,. Guidelines on prostate cancer. March 2025. https:\/\/d56bochluxqnz.cloudfront.net\/documents\/full-guideline\/EAU-EANM-ESTRO-ESUR-ISUP-SIOG-Guidelines-on-Prostate-Cancer-2025_updated.pdf. Accessed 12 Sep 2025."},{"key":"811_CR19","unstructured":"Food and Drug Administration. Incorporating voluntary patient preference information over the total product life cycle: draft guidance. 6 September 2024. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/incorporating-voluntary-patient-preference-information-over-total-product-life-cycle. Accessed 2 Sep 2025."},{"issue":"2","key":"811_CR20","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1007\/s40273-018-0734-2","volume":"37","author":"V Soekhai","year":"2019","unstructured":"Soekhai V, de Bekker-Grob EW, Ellis AR, Vass CM. Discrete choice experiments in health economics: past, present and future. Pharmacoeconomics. 2019;37(2):201\u201326. https:\/\/doi.org\/10.1007\/s40273-018-0734-2.","journal-title":"Pharmacoeconomics"},{"issue":"8","key":"811_CR21","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s40273-025-01495-y","volume":"43","author":"SPH Nouwens","year":"2025","unstructured":"Nouwens SPH, Marceta SM, Bui M, van Dijk D, Groothuis-Oudshoorn CGM, Veldwijk J, et al. The evolving landscape of discrete choice experiments in health economics: a systematic review. Pharmacoeconomics. 2025;43(8):879\u2013936. https:\/\/doi.org\/10.1007\/s40273-025-01495-y.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"811_CR22","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1016\/j.jval.2016.04.004","volume":"19","author":"AB Hauber","year":"2016","unstructured":"Hauber AB, Gonzalez JM, Groothuis-Oudshoorn CG, Prior T, Marshall DA, Cunningham C, et al. Statistical methods for the analysis of discrete choice experiments: a report of the ISPOR Conjoint Analysis Good Research Practices Task Force. Value Health. 2016;19(4):300\u201315. https:\/\/doi.org\/10.1016\/j.jval.2016.04.004.","journal-title":"Value Health."},{"issue":"1","key":"811_CR23","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.jval.2012.08.2223","volume":"16","author":"F Reed Johnson","year":"2013","unstructured":"Reed Johnson F, Lancsar E, Marshall D, Kilambi V, Muhlbacher A, Regier DA, et al. Constructing experimental designs for discrete-choice experiments: Report of the ISPOR Conjoint Analysis Experimental Design Good Research Practices Task Force. Value Health. 2013;16(1):3\u201313. https:\/\/doi.org\/10.1016\/j.jval.2012.08.2223.","journal-title":"Value Health"},{"issue":"4","key":"811_CR24","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.jval.2010.11.013","volume":"14","author":"JF Bridges","year":"2011","unstructured":"Bridges JF, Hauber AB, Marshall D, Lloyd A, Prosser LA, Regier DA, et al. Conjoint analysis applications in health\u2013a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14(4):403\u201313. https:\/\/doi.org\/10.1016\/j.jval.2010.11.013.","journal-title":"Value Health."},{"key":"811_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.euros.2021.10.003","volume":"36","author":"MJ Connor","year":"2022","unstructured":"Connor MJ, Genie MG, Burns D, Bass EJ, Gonzalez M, Sarwar N, et al. A systematic review of patients\u2019 values, preferences, and expectations for the treatment of metastatic prostate cancer. Eur Urol Open Sci. 2022;36:9\u201318. https:\/\/doi.org\/10.1016\/j.euros.2021.10.003.","journal-title":"Eur Urol Open Sci."},{"issue":"3","key":"811_CR26","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s40271-019-00360-3","volume":"12","author":"JM Gonzalez","year":"2019","unstructured":"Gonzalez JM. A guide to measuring and interpreting attribute importance. Patient. 2019;12(3):287\u201395. https:\/\/doi.org\/10.1007\/s40271-019-00360-3.","journal-title":"Patient"},{"issue":"10","key":"811_CR27","doi-asserted-by":"publisher","first-page":"3934","DOI":"10.1007\/s12325-024-02955-1","volume":"41","author":"B Hauber","year":"2024","unstructured":"Hauber B, Hong A, Hunsche E, Maculaitis MC, Collins SP. Patient preferences for attributes of androgen deprivation therapies in prostate cancer: a discrete choice experiment with latent class analysis. Adv Ther. 2024;41(10):3934\u201350. https:\/\/doi.org\/10.1007\/s12325-024-02955-1.","journal-title":"Adv Ther"},{"key":"811_CR28","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1382678","volume":"14","author":"Y Fan","year":"2024","unstructured":"Fan Y, Guo X, Campobasso D, He Z. Physician preferences for nonmetastatic castration-resistant prostate cancer treatment in China. Front Oncol. 2024;14:1382678. https:\/\/doi.org\/10.3389\/fonc.2024.1382678.","journal-title":"Front Oncol"},{"issue":"6","key":"811_CR29","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1007\/s40271-023-00638-7","volume":"16","author":"JM Gonzalez","year":"2023","unstructured":"Gonzalez JM, Ganguli A, Morgans AK, Tombal BF, Hotte SJ, Suzuki H, et al. Discrete-choice experiment to understand the preferences of patients with hormone-sensitive prostate cancer in the USA, Canada, and the UK. Patient. 2023;16(6):607\u201323. https:\/\/doi.org\/10.1007\/s40271-023-00638-7.","journal-title":"Patient"},{"key":"811_CR30","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.euros.2023.03.001","volume":"51","author":"D Menges","year":"2023","unstructured":"Menges D, Piatti MC, Omlin A, Cathomas R, Benamran D, Fischer S, et al. Patient and general population preferences regarding the benefits and harms of treatment for metastatic prostate cancer: a discrete choice experiment. Eur Urol Open Sci. 2023;51:26\u201338. https:\/\/doi.org\/10.1016\/j.euros.2023.03.001.","journal-title":"Eur Urol Open Sci"},{"issue":"5","key":"811_CR31","doi-asserted-by":"publisher","first-page":"6040","DOI":"10.1002\/cam4.5313","volume":"12","author":"DJ George","year":"2023","unstructured":"George DJ, Mohamed AF, Tsai JH, Karimi M, Ning N, Jayade S, et al. Understanding what matters to metastatic castration-resistant prostate cancer (mCRPC) patients when considering treatment options: a US patient preference survey. Cancer Med. 2023;12(5):6040\u201355. https:\/\/doi.org\/10.1002\/cam4.5313.","journal-title":"Cancer Med"},{"issue":"8","key":"811_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-052471","volume":"11","author":"H Uemura","year":"2021","unstructured":"Uemura H, Matsushima H, Yokomizo A, Kobayashi K, Arai G, Satoh T, et al. Unmet needs in non-metastatic castration-resistant prostate cancer from the Japanese patient perspective: a discrete choice experiment. BMJ Open. 2021;11(8):e052471. https:\/\/doi.org\/10.1136\/bmjopen-2021-052471.","journal-title":"BMJ Open"},{"issue":"6","key":"811_CR33","doi-asserted-by":"publisher","first-page":"367 e7","DOI":"10.1016\/j.urolonc.2020.12.014","volume":"39","author":"AM Rentz","year":"2021","unstructured":"Rentz AM, Mansukhani SG, Liu J, Lloyd AJ, Heidenreich S, Matza LS, et al. Patients\u2019 preferences for delaying metastatic castration-resistant prostate cancer: Combining health state and treatment valuation. Urol Oncol. 2021;39(6):367 e7-e17. https:\/\/doi.org\/10.1016\/j.urolonc.2020.12.014.","journal-title":"Urol Oncol"},{"key":"811_CR34","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1200\/GO.20.00358","volume":"7","author":"K Suzuki","year":"2021","unstructured":"Suzuki K, Grillo V, Chen Y, Singh S, Ledesma DA. Understanding treatment strategies and preferences in nonmetastatic castration-resistant prostate cancer from the Japanese physician perspective. JCO Glob Oncol. 2021;7:302\u201310. https:\/\/doi.org\/10.1200\/GO.20.00358.","journal-title":"JCO Glob Oncol"},{"issue":"18","key":"811_CR35","doi-asserted-by":"publisher","first-page":"6586","DOI":"10.1002\/cam4.3321","volume":"9","author":"S Srinivas","year":"2020","unstructured":"Srinivas S, Mohamed AF, Appukkuttan S, Botteman M, Ng X, Joshi N, et al. Patient and caregiver benefit-risk preferences for nonmetastatic castration-resistant prostate cancer treatment. Cancer Med. 2020;9(18):6586\u201396. https:\/\/doi.org\/10.1002\/cam4.3321.","journal-title":"Cancer Med"},{"issue":"1","key":"811_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-020-00631-4","volume":"20","author":"S Srinivas","year":"2020","unstructured":"Srinivas S, Mohamed AF, Appukkuttan S, Botteman M, Ng X, Joshi N, et al. Physician preferences for non-metastatic castration-resistant prostate cancer treatment. BMC Urol. 2020;20(1):73. https:\/\/doi.org\/10.1186\/s12894-020-00631-4.","journal-title":"BMC Urol"},{"issue":"2","key":"811_CR37","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1007\/s12325-018-0861-3","volume":"36","author":"HM de Freitas","year":"2019","unstructured":"de Freitas HM, Ito T, Hadi M, Al-Jassar G, Henry-Szatkowski M, Nafees B, et al. Patient preferences for metastatic hormone-sensitive prostate cancer treatments: a discrete choice experiment among men in three European countries. Adv Ther. 2019;36(2):318\u201332. https:\/\/doi.org\/10.1007\/s12325-018-0861-3.","journal-title":"Adv Ther"},{"issue":"4","key":"811_CR38","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1177\/1557988318776123","volume":"12","author":"M Nakayama","year":"2018","unstructured":"Nakayama M, Kobayashi H, Okazaki M, Imanaka K, Yoshizawa K, Mahlich J. Patient preferences and urologist judgments on prostate cancer therapy in Japan. Am J Mens Health. 2018;12(4):1094\u2013101. https:\/\/doi.org\/10.1177\/1557988318776123.","journal-title":"Am J Mens Health"},{"issue":"11","key":"811_CR39","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1080\/13696998.2017.1362410","volume":"20","author":"R Goto","year":"2017","unstructured":"Goto R, Uda A, Hiroi S, Iwasaki K, Takashima K, Oya M. Cost analysis of leuprorelin acetate in Japanese prostate cancer patients: comparison between 6-month and 3-month depot formulations. J Med Econ. 2017;20(11):1155\u201362. https:\/\/doi.org\/10.1080\/13696998.2017.1362410.","journal-title":"J Med Econ"},{"issue":"4","key":"811_CR40","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1016\/j.clinthera.2017.02.009","volume":"39","author":"L Eliasson","year":"2017","unstructured":"Eliasson L, de Freitas HM, Dearden L, Calimlim B, Lloyd AJ. Patients\u2019 preferences for the treatment of metastatic castrate-resistant prostate cancer: a discrete choice experiment. Clin Ther. 2017;39(4):723\u201337. https:\/\/doi.org\/10.1016\/j.clinthera.2017.02.009.","journal-title":"Clin Ther"},{"issue":"1","key":"811_CR41","doi-asserted-by":"publisher","DOI":"10.1186\/s12894-016-0182-2","volume":"16","author":"H Uemura","year":"2016","unstructured":"Uemura H, Matsubara N, Kimura G, Yamaguchi A, Ledesma DA, DiBonaventura M, et al. Patient preferences for treatment of castration-resistant prostate cancer in Japan: a discrete-choice experiment. BMC Urol. 2016;16(1):63. https:\/\/doi.org\/10.1186\/s12894-016-0182-2.","journal-title":"BMC Urol"},{"issue":"2","key":"811_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/sj.pcan.4500992","volume":"11","author":"A Lloyd","year":"2008","unstructured":"Lloyd A, Penson D, Dewilde S, Kleinman L. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer. Prostate Cancer Prostatic Dis. 2008;11(2):153\u20139. https:\/\/doi.org\/10.1038\/sj.pcan.4500992.","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"7436","key":"811_CR43","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1136\/bmj.37972.497234.44","volume":"328","author":"M Sculpher","year":"2004","unstructured":"Sculpher M, Bryan S, Fry P, de Winter P, Payne H, Emberton M. Patients\u2019 preferences for the management of non-metastatic prostate cancer: discrete choice experiment. BMJ. 2004;328(7436):382. https:\/\/doi.org\/10.1136\/bmj.37972.497234.44.","journal-title":"BMJ"},{"issue":"7","key":"811_CR44","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1111\/jgs.14795","volume":"65","author":"KM Winters-Stone","year":"2017","unstructured":"Winters-Stone KM, Moe E, Graff JN, Dieckmann NF, Stoyles S, Borsch C, et al. Falls and frailty in prostate cancer survivors: current, past, and never users of androgen deprivation therapy. J Am Geriatr Soc. 2017;65(7):1414\u20139. https:\/\/doi.org\/10.1111\/jgs.14795.","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"811_CR45","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaccao.2024.09.012","volume":"6","author":"DP Leong","year":"2024","unstructured":"Leong DP, Guha A, Morgans AK, Niazi T, Pinthus JH. Cardiovascular risk in prostate cancer: JACC: CardioOncology state-of-the-art review. JACC CardioOncol. 2024;6(6):835\u201346. https:\/\/doi.org\/10.1016\/j.jaccao.2024.09.012.","journal-title":"JACC CardioOncol"},{"issue":"10","key":"811_CR46","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1111\/j.1742-1241.2010.02463.x","volume":"64","author":"M Emberton","year":"2010","unstructured":"Emberton M. Medical treatment of benign prostatic hyperplasia: physician and patient preferences and satisfaction. Int J Clin Pract. 2010;64(10):1425\u201335. https:\/\/doi.org\/10.1111\/j.1742-1241.2010.02463.x.","journal-title":"Int J Clin Pract"},{"issue":"6","key":"811_CR47","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1007\/s40271-021-00520-4","volume":"14","author":"H Collacott","year":"2021","unstructured":"Collacott H, Soekhai V, Thomas C, Brooks A, Brookes E, Lo R, et al. A systematic review of discrete choice experiments in oncology treatments. Patient. 2021;14(6):775\u201390. https:\/\/doi.org\/10.1007\/s40271-021-00520-4.","journal-title":"Patient"},{"issue":"5","key":"811_CR48","first-page":"e121","volume":"16","author":"SB Zeliadt","year":"2010","unstructured":"Zeliadt SB, Moinpour CM, Blough DK, Penson DF, Hall IJ, Smith JL, et al. Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care. 2010;16(5):e121-30.","journal-title":"Am J Manag Care"},{"issue":"12","key":"811_CR49","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1200\/JCO.18.01091","volume":"37","author":"R Jayadevappa","year":"2019","unstructured":"Jayadevappa R, Chhatre S, Gallo JJ, Wittink M, Morales KH, Lee DI, et al. Patient-centered preference assessment to improve satisfaction with care among patients with localized prostate cancer: a randomized controlled trial. J Clin Oncol. 2019;37(12):964\u201373. https:\/\/doi.org\/10.1200\/JCO.18.01091.","journal-title":"J Clin Oncol"},{"key":"811_CR50","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2023.1192770","volume":"14","author":"R Janssens","year":"2023","unstructured":"Janssens R, Barbier L, Muller M, Cleemput I, Stoeckert I, Whichello C, et al. How can patient preferences be used and communicated in the regulatory evaluation of medicinal products? Findings and recommendations from IMI PREFER and call to action. Front Pharmacol. 2023;14:1192770. https:\/\/doi.org\/10.3389\/fphar.2023.1192770.","journal-title":"Front Pharmacol"},{"issue":"5","key":"811_CR51","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1007\/s40271-020-00434-7","volume":"13","author":"Y Sugitani","year":"2020","unstructured":"Sugitani Y, Sugitani N, Ono S. Quantitative preferences for lung cancer treatment from the patients\u2019 perspective: a systematic review. Patient Auckl N Z. 2020;13(5):521\u201336. https:\/\/doi.org\/10.1007\/s40271-020-00434-7.","journal-title":"Patient Auckl N Z"},{"key":"811_CR52","doi-asserted-by":"crossref","unstructured":"Kearney M, Janssens R, Quaife M, Trapali M, Thomas C. Patient and caregiver preferences for the treatment of locally advanced or metastatic urothelial carcinoma (la\/mUC): Results of a targeted literature review (TLR). In: Presented at ASCO Genitourinary Cancers Symposium; 13-15 February 2025. San Francisco, CA, USA.","DOI":"10.1200\/JCO.2025.43.5_suppl.755"},{"issue":"8","key":"811_CR53","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1016\/j.socscimed.2006.12.007","volume":"64","author":"E Lancsar","year":"2007","unstructured":"Lancsar E, Louviere J, Flynn T. Several methods to investigate relative attribute impact in stated preference experiments. Soc Sci Med. 2007;64(8):1738\u201353. https:\/\/doi.org\/10.1016\/j.socscimed.2006.12.007.","journal-title":"Soc Sci Med"}],"container-title":["The Patient - Patient-Centered Outcomes Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40271-026-00811-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40271-026-00811-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T13:26:26Z","timestamp":1787664386000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40271-026-00811-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,12]]},"references-count":53,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["811"],"URL":"https:\/\/doi.org\/10.1007\/s40271-026-00811-8","relation":{},"ISSN":["1178-1653","1178-1661"],"issn-type":[{"value":"1178-1653","type":"print"},{"value":"1178-1661","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,12]]},"assertion":[{"value":"29 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"BH, AH, JC, DR, MR, and SD are employees of Pfizer and may hold stocks\/stock options for Pfizer, which sponsored this review and the development of this publication. VW is an employee of RTI Health Solutions and is an Editorial Board Member of\n                      The Patient\n                      . She was not involved in the selection of peer reviewers for the manuscript nor in any of the subsequent editorial decisions. SC has previously been a consultant for Pfizer. NA reports no honoraria related to this work and reports travel support from Pfizer, Exelixis, and Johnson & Johnson to attend meetings of the respective pharmaceutical companies. Research funding has been provided to NA\u2019s institution by the following: Arnivas, Astellas, Astra Zeneca, Bavarian Nordic, Bayer, Bristol Myers Squibb, Calithera, Celldex, Clovis, Crispr, Eisai, Eli Lilly, EMD Serono, Exelixis, Genentech, Gilead, Glaxo Smith Kline, Immunomedics, Janssen, Lava, Medivation, Merck, Nektar, Neoleukin, New Link Genetics, Novartis, Oric, Pfizer, Prometheus, Rexahn, Roche, Sanofi, Seattle Genetics, Takeda, and Tracon.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The data that support the findings of this literature review are available in the article itself or its supporting information.","order":2,"name":"Ethics","label":"Data Availability Statement","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors made a significant contribution to this work, whether that is in the conception, study design, execution, analysis, or interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work.","order":3,"name":"Ethics","label":"Authors\u2019 Contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}